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Background: Drug eluting stents (DES) significantly reduce the need for target lesion revascularization (TLR) compared to bare metal stents (BMS) 
but may be associated with increased risk of late stent thrombosis (ST). Whether the favorable cost-effectiveness of DES in reducing TLR compared 
to BMS seen in randomized clinical trials is altered by ST in “off-label” DES use is uncertain.
Methods: Two years of clinical follow-up were available for 1,147 BMS and 1,247 DES patients from the Wake Forest registry. Index PCI costs were 
estimated using Medicare DRG reimbursement rates for 2004. Total cost for TLR and ST outcomes were converted to 2004 dollars. Physician fees 
were estimated from the 2004 North Carolina fee schedule, and clopidogrel cost was set at adjusted wholesale price for 2004. Cost effectiveness 
ratios (CER) were calculated for mean cost difference per net TLR and ST avoided.
Results: DES and BMS baseline characteristics were well matched, with 80% DES and 75% BMS “off-label” (p=0.004). Number of stents placed 
and length of stay per patient were similar for DES and BMS, 1.5 vs 1.6 (p=0.47); 3.6 vs 3.3 days (p=0.95), respectively. Cost of index DES 
hospitalization was $1,145 higher than BMS (p<0.001). At 2 years TLR incidence was 4.4% with DES and 8.6% with BMS (DES 4.2% lower, p<0.001), 
with ST incidence of 1.0% with DES and 0.7% with BMS (DES 0.3% higher, p=0.48). Mean cost of hospitalization for TLR without ST was $17,018 
vs $19,109 for TLR with ST (p=0.27). Aggregate two-year costs including recommended duration of clopidogrel therapy were $731 higher with DES 
compared to BMS (p<0.001). CER for net TLR outcomes including ST was $17,405 per TLR avoided. Sensitivity analysis assuming DES ST incidence 
exceeded BMS by 0.6% resulted in a CER of $20,156 per TLR and ST avoided.
Conclusion: In routine use of DES at 2 years, the vast majority of which were “off label”, the cost of DES with respect to TLR clinical outcomes 
including ST was $17,405 per TLR avoided. These data provide a benchmark for use of DES vs BMS in routine clinical practice.
